Argenx (ARGX)
(Real Time Quote from BATS)
$393.37 USD
-0.41 (-0.10%)
Updated May 7, 2024 12:28 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
argenex SE [ARGX]
Reports for Purchase
Showing records 1 - 20 ( 277 total )
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Long Overlooked, Graves Disease Goes In Vogue With New Approaches
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Its Prime Time for FcRn with Vyvgart in the Spotlight
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
With the Present Bright With Vyvgart, argenx Begins to Highlight a Future Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Vyvgart Primed for Another Year of Dominance
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Equity Strategy - Wedbush Equity Strategy - Market Commentary
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Strong Sales Performance of Vyvgart; Eyes on Empasiprubart; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Another Setback Offers a Reminder That Drug Development is Hard; Price Target Down to $451
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Company: argenex SE
Industry: Medical - Biomedical and Genetics
Vyvgart Fails to Advance in ITP; Price Target Down to $582
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D